Peter J. Rossi, MD, discusses innovations and advances in low-dose-rate (LDR) and high-dose-rate (HDR) prostate brachytherapy as well as American Brachytherapy Society (ABS) initiatives and training opportunities. Dr. Rossi explains that innovations have resulted in brachytherapy treatment that is evidence-based, innovative, efficient, cost-effective, flexible, yields highly personalized treatment, and is of high value to multidisciplinary teams and to patients.